Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that has attracted considerable interest in preclinical research due to its highly selective receptor binding profile. Unlike earlier generation secretagogues, Ipamorelin has been observed to stimulate growth hormone release in animal models without significantly affecting cortisol or prolactin levels, making it a valuable tool for researchers investigating the growth hormone axis in isolation.
What Is Ipamorelin?
Ipamorelin is a five-amino-acid peptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 and a molecular weight of approximately 711.9 Daltons. It was originally developed in the late 1990s as part of a research program investigating selective growth hormone secretagogues. Ipamorelin functions by binding to the growth hormone secretagogue receptor type 1a, commonly referred to as GHSR-1a or the ghrelin receptor, which is expressed in the anterior pituitary gland.
What distinguishes Ipamorelin from other GHSR-1a agonists such as GHRP-6 and GHRP-2 is its selectivity. In preclinical assays, Ipamorelin demonstrated potent growth hormone releasing activity at doses that did not produce statistically significant elevations of adrenocorticotropic hormone, cortisol, or prolactin. This selectivity has made it a preferred research tool in studies where confounding hormonal effects must be minimized.
GHSR-1a Binding and Signaling Research
The ghrelin receptor GHSR-1a is a G protein-coupled receptor that plays a central role in the regulation of growth hormone secretion. In-vitro receptor binding studies have demonstrated that Ipamorelin engages GHSR-1a with high affinity and triggers intracellular calcium mobilization through the Gq/11 signaling cascade. These binding characteristics have been characterized using competitive radioligand displacement assays and functional calcium flux measurements in cell lines expressing recombinant GHSR-1a.
Researchers studying the pharmacology of ghrelin receptor signaling have used Ipamorelin as a reference agonist to compare against novel compounds. Its well-characterized binding profile and dose-response curve make it useful as a positive control in screening assays for new growth hormone secretagogue candidates.
Preclinical Research Areas
In animal models, Ipamorelin has been investigated across several research domains. Studies in rodent models have examined its effects on pulsatile growth hormone release patterns, demonstrating that it can amplify endogenous growth hormone pulses without disrupting the natural secretory rhythm. This characteristic has made it a subject of interest in research examining how growth hormone pulse dynamics differ from sustained elevation.
Additional preclinical investigations have explored Ipamorelin in the context of body composition research in animal models, where changes in lean mass and adipose tissue distribution were measured following administration. Bone density research in ovariectomized rat models has also been conducted, examining the relationship between growth hormone secretagogue administration and markers of bone turnover.
Research into age-related changes in the growth hormone axis has employed Ipamorelin to study how secretagogue responsiveness varies with age in rodent models. These studies have contributed to the understanding of somatopause, the age-related decline in growth hormone output, at a mechanistic level.
Handling and Storage Protocols
Ipamorelin is supplied as a lyophilized white powder and should be stored at negative twenty degrees Celsius for long-term preservation. Under these conditions, the lyophilized peptide is stable for twelve months or longer. For reconstitution, bacteriostatic water is the most commonly used solvent in research settings. The peptide dissolves readily and produces a clear, colorless solution.
Once reconstituted, Ipamorelin solutions should be refrigerated at two to eight degrees Celsius and used within three to four weeks. Aliquoting into single-use volumes at the time of reconstitution is recommended to avoid repeated freeze-thaw cycles. As with all research peptides, the vial should be protected from direct light exposure, and researchers should allow the vial to equilibrate to room temperature before opening to prevent moisture ingress from condensation.
Quality Verification
Researchers should verify each lot of Ipamorelin using a current Certificate of Analysis from an independent analytical laboratory. HPLC purity should be confirmed at ninety-nine percent or higher, and the molecular identity should be verified by electrospray ionization mass spectrometry with the observed mass matching the theoretical value within acceptable tolerance. Ipamorelin is intended exclusively for in-vitro and preclinical research use and is not approved for human consumption or clinical application.